Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells.

At Kite, a Gilead Company, our singular focus is cell therapy to treat and potentially cure cancer. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. 

Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many people with cancer as possible who may benefit. 

Cancer is personal to us. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. 

Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about changing the future of cancer treatment, let’s talk.

See our community guidelines: http://bit.ly/2DznMNw

Kite Pharma

For innovative treatments like CAR T-cell therapies to reach as many patients as possible who may benefit, it takes a team effort – including the care and precision to manufacture them. Our #celltherapy specialists, like Yolanda, play a critical role in transforming T cells into #cancer fighting therapies.

#KiteNews: Today, we announced that the U.S. FDA has approved a label update for our CAR T-cell therapy to include overall survival data from a primary analysis of our therapy versus standard of care as second-line treatment with curative intent. 
 
Read more: https://bit.ly/41zskhh

Extending our warmest gratitude to everyone who has supported our mission to change the way cancer is treated this year. We wish you a happy, healthy and joyful year ahead.

Ahead of the holidays, Kite colleagues in the LA area came together to support Stuff the Bus, an annual toy drive hosted by Southern California firefighters, the LA County Fire Department, Marine Toys for Tots Foundation and ABC7 Los Angeles. Thank you to our shuttle provider WeDriveU and everyone who helped make the holidays special for local youth.

Thank you to the American Society of Hematology for a great #ASH23. We enjoyed presenting our data and discussing the latest advancements in treating #bloodcancers with colleagues and peers from around the world.

#KiteNews: Today, we shared analyses of three #CARTcell therapy studies that explore curative potential for patients living with several sub-types of relapsed/refractory non-Hodgkin lymphoma at the American Society of Hematology Annual Meeting. #ASH23  

Read more: https://bit.ly/3NmScXK

#KiteNews: Announcing new findings from a follow-up analysis of #CARTcell therapy from the first study of its kind in patients with high-risk, large B-cell lymphoma. The study’s results were presented as part of an oral presentation at the American Society of Hematology Annual Meeting. #ASH23  

Read more: https://bit.ly/4agtqlF

We’re pleased to share that our partner Arcellx will present new data in relapsed/refractory multiple myeloma at the American Society of Hematology Annual Meeting. #ASH23

It was a pleasure welcoming Kevin Anderson, Secretary of the Maryland Department of Commerce, to our state-of-the-art cell therapy manufacturing facility in Frederick. Our team had the opportunity to show him how cell therapies are made for each individual patient and take him on a tour of our site.

Cell therapies are changing the way cancer is treated by giving patients with certain #bloodcancers more options than ever before. But what does this innovative therapy hold for the future?  
 
Ahead of #ASH23, hear from Kite’s Global Head of Clinical Development Frank Neumann, MD, PhD, and Global Head of Research Priti Hegde, PhD, on how far the science has progressed and where it is headed.

COM:KITEPHARMA

Kite Pharma, Inc.

Analysis Not Available